NT-0796 manufacturers
- NT-0796
-
- $98.00
-
2026-07-31
- CAS:2272917-13-0
- Purity: 97.00%
- Supply Ability: 10g
|
| | NT-0796 Basic information |
| Product Name: | NT-0796 | | Synonyms: | NT-0796;2-Pyrimidinepropanoic acid, α-[[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]oxy]-, 1-methylethyl ester, (αR)-;Ruvonoflast (NT-0796);Isopropyl (R)-2-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)oxy)-3-(pyrimidin-2-yl)propanoate | | CAS: | 2272917-13-0 | | MF: | C23H27N3O4 | | MW: | 409.48 | | EINECS: | | | Product Categories: | | | Mol File: | 2272917-13-0.mol |  |
| | NT-0796 Chemical Properties |
| Boiling point | 526.8±50.0 °C(predicted) | | density | 1.275±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | solubility | Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml | | form | Solid | | pka | 12.96±0.20(predicted) | | color | White to off-white |
| | NT-0796 Usage And Synthesis |
| Description | NT-0796 is an inhibitor of the NOD-like receptor protein 3 (NLRP3) inflammasome and a prodrug form of NDT-19795.1 It selectively inhibits NLRP3 over NLR family CARD domain-containing protein 4 (NLRC4) at 3 nM, as well as a panel of 121 other receptors at 10 µM, but does inhibit the serotonin (5-HT) receptor subtype 5-HT2B by 90% at 10 µM. NT-0796 inhibits LPS- and ATP-induced IL-1β release in isolated human peripheral blood mononuclear cells (PBMCs) and whole blood (IC50s = 0.32 and 6.8 nM, respectively), however, it does not affect LPS-induced TNF-α or IL-6 release in isolated human PBMCs (IC50s = >2 µM for both), indicating NLRP3 selectivity. It decreases body weight, food intake, and plasma levels of total cholesterol, HDL, and proprotein convertase subtilisin kexin type 9 (PCSK9) in a model of high-fat diet-induced obesity using transgenic mice expressing human carboxylesterase-1 (CES1), the enzyme that converts NT-0796 to NDT-19795, when administered at a dose of 100 mg/kg three times per day.2WARNING This product is not for human or veterinary use. | | References | [1] DAVID HARRISON. Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.[J]. Journal of Medicinal Chemistry, 2023: 14897-14911. DOI: 10.1021/acs.jmedchem.3c01398
[2] PETER THORNTON. Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796.[J]. Journal of Pharmacology and Experimental Therapeutics, 2024: 813-826. DOI: 10.1124/jpet.123.002013 |
| | NT-0796 Preparation Products And Raw materials |
|